Adicet Bio, Inc.

**Signal Note: RA Capital Initiation in Adicet Bio (ACET)** RA Capital's $8M entry into ACET signals confidence in the firm's allogeneic gamma-delta T-cell platform, particularly for hematologic malignancies where off-the-shelf cell therapy offers manufacturing and cost advantages over autologous approaches. The timing likely reflects upcoming clinical readouts or partnership catalysts, though near-term value will depend on efficacy data from ongoing trials and addressing manufacturing scalability—a historically challenging constraint for cell therapies.